Sorrento Therapeutics, Inc (NASDAQ:SRNE) achieved significant progress in developing COVISHIELD using Mount Sinai’s IP (the Icahn School of Medicine at Mount Sinai).
Sorrento utilized a license for IP developed by a team of scientists at Mount Sinai to develop an innovative formulation to neutralize the effects of SARS-CoV-2.
Inks an exclusive pact
The company entered an exclusive pact with Mount Sinai to utilize the antibodies that can neutralize the properties of the SARS-CoV-2 virus. As per the terms of the deal, Mount Sinai and Sorrento can collaborate to develop HMA (humanized monoclonal antibodies) for other therapeutic applications.
COVISHIELD comprises two monoclonal antibodies that are developed to get protection from emerging variants or existing SARS-CoV-2.
Sorrento developed monoclonal antibody combinations considering the early days of pandemic and emerging variants of the virus from across the world. It can protect against the coronavirus variants like those found in Brazil/ Japan, South Africa, and the UK.
Positive findings from the laboratory tests will support in FDA evaluation of its COVISHIELD and future development efforts. COVISHIELD is a result of using the development resources and discovery efforts of Sorrento together with Mount Sinai’s IP.
COVISHIELD protects from emerging and existing COVID-19
Sorrento is developing COVISHIELD to provide a rapid means for people to safeguard from pandemic threat pathogens and the prevailing/ emerging coronavirus variants.
Henry Ji, CEO of Sorrento, said the company is excited with the antibody candidates developed so far to contain the spread of coronavirus and provide protection against coronavirus.
The Sorrento team is committed to quickly bringing up a cocktail to protect from the upcoming and existing coronavirus variants. Sorrento expects to collaborate with Mount Sinai to develop anti-cancer and anti-viral therapeutics.
COF to commence clinical trial of Socazolimab
China Oncology Focus Limited (COF) said it received clearance to commence the phase 2 clinical study of Socazolimab, for which a license is obtained from Sorrento.
COF will conduct a double-blinded, randomized, and multicenter trial of Socazolimab in combination with chemotherapy to cure small cell lung cancer. It is an associate of Lee’s Pharmaceutical Holdings Limited.
In phase 1b clinical trials, Socazolimab showed a promising safety profile and efficacy in patients with small lung cancer when treated in combination with etoposide and carboplatin.
THC Biomed Intl Ltd (OTCMKTS: THCBF) Amends its Health Canada Licence to Include Three Strata Units at its Acland Road Location
Post Views: 5 It took only a year for THC Biomed Intl Ltd (OTCMKTS: THCBF) to obtain a rare license...
Tetra Bio-Pharma Inc. (OTCMKTS: TBPMF) Obtains an Approval of the Proposed Protocol Modifications to Accelerate the REBORN Study
Post Views: 37 Clinical trials are an essential component of any drug discovery and development program. Innovative research initiatives are...
The Appointment of Philip Goldberg, Formerly of Green Leaf Medical, to the Board of Directors of Columbia Care Inc. (OTCMKTS: CCHWF)
Post Views: 6 The growing acceptance and recognition of marijuana for its medical purposes has made an impact on cannabis...
Surna Inc, (OTCMKTS: SRNA) Expands its Line of Curated HVACD Family Products with the Introduction of EnviroPro™ Air Handler
Post Views: 6 The cultivation of cannabis comes with a myriad of challenges. Designing cultivation facilities and deploying the systems...
Mydecine Innovations Group Inc. (OTCMKTS: MYCOF) Supports the Launch of Version 2.0, a Digital Health Platform by its Subsidiary Mindleap Health
Post Views: 3 The COVID 19 pandemic took the world by storm and has left hundreds of thousands of people...
HempMeds Latin American Operations, a subsidiary of Medical Marijuana, Inc. (OTCMKTS: MJNA), Announces a 12% Revenue Increase in June 2021 Compared to June 2020
Post Views: 18 What comes to mind when you hear the words, “Medical marijuana?” It is seemingly regarded as the...